Results 21 to 30 of about 211,312 (294)
Journal of Hematology & Oncology, 2021 Resistance to anti-cancer monoclonal antibody (mAb) therapy remains a clinical challenge. Previous work in our laboratory has shown that T cell help in the form of interleukin-2 maintains long-term NK cell viability and NK cell-mediated antibody ...
Zhaoming Wang +4 more
doaj +1 more source
Haematologica, 2015 Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of daratumumab, we explored the possibility of improving daratumumab-mediated ...
Inger S. Nijhof +8 more
doaj +1 more source
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Cells, 2020 Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a ...
Ilaria Saltarella +9 more
doaj +1 more source
Real time assays for quantifying cytotoxicity with single cell resolution. [PDF]
PLoS ONE, 2013 A new live cell-based assay platform has been developed for the determination of complement dependent cytotoxicity (CDC), antibody dependent cellular cytotoxicity (ADCC), and overall cytotoxicity in human whole blood.
Sonny C Hsiao +5 more
doaj +1 more source
Cells, 2021 The epidermal growth factor receptor (EGFR) contributes to tumor malignancy via gene amplification and protein overexpression. Previously, we developed an anti-human EGFR (hEGFR) monoclonal antibody, namely EMab-134, which detects hEGFR and dog EGFR ...
Guanjie Li +8 more
doaj +1 more source
Frontiers in Immunology, 2017 Immunotherapy using broadly neutralizing antibodies (bNAbs) endowed with Fc-mediated effector functions has been shown to be critical for protecting or controlling viral replication in animal models.
Nicole F. Bernard +12 more
doaj +1 more source
IgG Fc engineering to modulate antibody effector functions
Protein & Cell, 2017 Therapeutic monoclonal antibodies are among the most effective biotherapeutics to date. An important aspect of antibodies is their ability to bind antigen while at the same time recruit immune effector functions.
Xinhua Wang +2 more
doaj +1 more source
Antibody - Dependent Cell - Mediated Cytotoxicity in Sheep
Acta Veterinaria Scandinavica, 1985 The ability of sheep leukocytes to mediate antibody — dependent cell-mediated cytotoxicity (ADCC) and that of sheep serum IgG1 and IgG2 to induce ADCC were investigated. Partial characterization of effector cells was attempted. These investigations revealed that ADCC occurs in sneep.
openaire +3 more sources
Antibodies, 2018 Monoclonal antibody (mAb) therapeutics have a promising outlook within the pharmaceutical industry having made positive strides in both research and development as well as commercialisation, however this development has been hampered by manufacturing ...
Arathi Kizhedath +2 more
doaj +1 more source
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
Frontiers in Oncology, 2021 Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM) cells have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody ...
Alessandra Romano +9 more
doaj +1 more source